migalastat
Sponsor SNY · listed as SNY
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
migalastat is a clinical-stage drug asset sponsored by SNY, listed as SNY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 31, 2026 (day precision, medium confidence), tied to trial NCT04020055. The asset is in Phase 3 and currently active not recruiting, studied in Fabry Disease. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2026-12-31
As disclosedDec 31, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT04020055
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAmicus Therapeutics
Listed asSNY
Condition(s)Fabry Disease
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More SNY catalysts